# SYNDAX PHARMACEUTICALS INC (SNDX)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/SNDX/

- Reporting holders: 5
- Reported value: $261.3K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Post Resch Tallon Group Inc.](https://holderbook.com/funds/2054476-post-resch-tallon-group-inc/) | $231.2K | 12,300 | 0.2% | 5 |
| [Versant Capital Management, Inc](https://holderbook.com/funds/1735057-versant-capital-management-inc/) | $15.9K | 844 | 0.0% | 6 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $6.5K | 345 | 0.0% | 12 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $6.4K | 339 | 0.0% | 12 |
| [MassMutual Private Wealth & Trust, FSB](https://holderbook.com/funds/1103653-massmutual-private-wealth-trust-fsb/) | $1.3K | 71 | 0.0% | 19 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 5 | $261.3K |
| Q2 2026 | 244 | $2.6B |
| Q1 2026 | 247 | $2.4B |
| Q4 2025 | 231 | $2.2B |
| Q3 2025 | 234 | $1.6B |
| Q2 2025 | 218 | $995.9M |
| Q1 2025 | 223 | $1.3B |
| Q4 2024 | 220 | $1.3B |
| Q3 2024 | 211 | $1.8B |
| Q2 2024 | 195 | $1.8B |
| Q1 2024 | 189 | $2.3B |
| Q4 2023 | 178 | $2.0B |